United States securities and exchange commission logo





                               August 7, 2020

       Robert Berman
       Chief Executive Officer and Director
       Hancock Jaffe Laboratories, Inc.
       70 Doppler
       Irvine, CA 92618

                                                        Re: Hancock Jaffe
Laboratories, Inc.
                                                            Preliminary Proxy
Statement on Schedule 14A
                                                            Filed July 24, 2020
                                                            File No. 001-38325

       Dear Mr. Berman:

              We have reviewed your filing and have the following comment. In
some of our
       comments, we may ask you to provide us with information so we may better
understand your
       disclosure.

              Please respond to the comment within ten business days by
providing the requested
       information or advise us as soon as possible when you will respond. If
you do not believe our
       comment applies to your facts and circumstances, please tell us why in
your response.

                                                        After reviewing your
response to the comment, we may have additional comments.

       Preliminary Proxy Statement filed July 24, 2020

       Proposal No. 1: The Authorized Share Proposal, page 8

   1.                                                   We note one of the
reasons listed for the proposal to increase the number of authorized
                                                        shares is that the
company does not have a sufficient amount of authorized shares to issue
                                                        additional stock in
connection with a potential merger between the company and Catheter
                                                        Precision, Inc., as
described in a non-binding letter of intent between the parties, dated
                                                        May 22, 2020. No
further information is provided regarding this transaction and the letter
                                                        of intent has not been
filed as a material agreement to date. Note A to Schedule 14A
                                                        provides that where a
solicitation of security holders is for the purpose of approving the
                                                        authorization of
additional securities which are to be used to acquire another specified
                                                        company, and the
registrants' security holders will not have a separate opportunity to vote
                                                        upon the transaction,
the solicitation to authorize the securities is also a solicitation with
                                                        respect to the
acquisition. Under those facts, information required by Items 11, 13 and 14
                                                        shall be furnished.
Please advise us whether the company's shareholders will have a
 Robert Berman
Hancock Jaffe Laboratories, Inc.
August 7, 2020
Page 2
         separate opportunity to vote on the Catheter Precision transaction. If
not, please revise the
         proxy statement to include the additional disclosure required.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

         You may contact Laura Crotty at (202) 551-7614 or Joe McCann at (202)
551-6262.



FirstName LastNameRobert Berman                                 Sincerely,
Comapany NameHancock Jaffe Laboratories, Inc.
                                                                Division of
Corporation Finance
August 7, 2020 Page 2                                           Office of Life
Sciences
FirstName LastName